Taiho Ventures logomarkTaiho Ventures

01/03Milestone

A decade of backing biotech innovation

Since 2016, Taiho Ventures has invested in more than 30 companies developing novel therapeutics — with multiple public listings and acquisitions by Johnson & Johnson, Eli Lilly, Sanofi, and Merck.

Taiho's 10-year announcement
10 Years Anniversary

02/03Portfolio

Arcus Biosciences: where it began

Our first portfolio company is now a public immuno-oncology company (NYSE: RCUS) — and granted Taiho Pharmaceutical exclusive licenses to five pipeline programs in select Asian markets.

Visit Arcus Biosciences
Arcus Biosciences

03/03Portfolio

Halda Therapeutics: a $3.05B exit

Halda — built on its first-in-class RIPTAC “hold-and-kill” platform for precision oncology — was acquired by Johnson & Johnson for $3.05 billion, the portfolio's largest exit.

The J&J acquisition
Halda TherapeuticsJohnson & Johnson
NextPortfolio · Arcus

Who we are

Taiho Ventures is the corporate venture arm of Taiho Pharmaceutical — investing where the science is strategically relevant, and backing it for the long term.

By the numbers

2016 — 2026 · a decade

0

Companies backed

Early-stage & private, since 2016.

$3.05B

Largest exit — Halda Therapeutics → Johnson & Johnson

4 realized exits · Merck · J&J · Lilly · Sanofi

See the full portfolio →
Public 5Acquired 4Private 14

What we look for

01 / 04

Four dimensions shape every investment we make.

Our investment focus

We invest in science strategically relevant to Taiho Pharmaceutical — primarily research through pre-IND, opportunistically to proof of concept.

SectorsTherapeutic areasModalityGeography
What we back

Sectors

Drug discovery rooted in first-in-class or new-biology approaches, platform technologies, and spin-outs from Taiho pipelines — with medical device, diagnostics, and digital health considered opportunistically.

Drug discoveryPlatform technologiesPipeline spin-outsMedical deviceDiagnosticsDigital health
SectorsTherapeutic areasModalityGeography
Where we focus

Therapeutic areas

A core focus in oncology, extending into immunology and allergy, urology, bone and muscle, and orphan disease where the science is strategically relevant.

OncologyImmunology and allergyUrologyBone and muscleOrphan disease
SectorsTherapeutic areasModalityGeography
Modality-agnostic

Modality

Small molecules and biologics, with gene and cell therapy considered opportunistically.

Small moleculesBiologicsGene and cell therapy
SectorsTherapeutic areasModalityGeography
Where we invest

Geography

Global investing, concentrated in the United States, Europe, and Japan, and connected to Taiho Pharmaceutical's R&D and commercial network.

United StatesEuropeJapan

Portfolio

Our portfolio companies

Taiho Ventures invests in the science behind the next generation of cancer therapies. These are the companies we've backed — spanning private innovators, public companies, and successful exits.

See the full portfolio →
Public 5Exit 4Private 14
Arcus BiosciencesHarpoon TherapeuticsDren BiocellvieEpi BiologicsLight Horse TherapeuticsNormunityTransition Bio
ORIC PharmaceuticalsHalda TherapeuticsAnavo TherapeuticsCullinanIncendia TherapeuticsMagnet BiomedicineSTORM TherapeuticsVertero
Werewolf TherapeuticsOrna TherapeuticsBreakpoint TherapeuticsDelphia TherapeuticsLiberoTheraNextCureTheo

Our team

A senior team, end to end.

Investors and drug developers who have run programs, sat on boards, and seen the science from discovery to exit. Select anyone to read their full background.

More about us →

Our office

In the heart of Sand Hill Road

Based in Menlo Park, California, our team operates at the center of the venture community, connecting breakthrough innovation with Taiho Pharmaceutical's global network.

United States · Headquarters

Menlo Park, CA

Taiho Ventures, LLC
2420 Sand Hill Road, Suite 203
Menlo Park, CA 94025-6940
Get directions →
Taiho Ventures office at 2420 Sand Hill Road, Menlo Park

Menlo Park, CA

37.4226° N 122.2026° W